The fibrinolytic system
Recent advances

FRED V. LUCAS, MD AND MICHAEL L. MILLER, DO

The fibrinolytic system is the subject of renewed and intense interest. As understanding of its complexity at the biochemical level has increased, appreciation of the role of this system in the pathophysiology of cardiovascular disease has grown. In addition, techniques in molecular biology have been applied to various proteins in the system to produce larger quantities of traditional and genetically engineered plasminogen activators. Many of these advances at a biochemical and molecular level will be increasingly translated into clinical medical practice and practical clinical laboratory tests. This review highlights some of these advances and the laboratory tests that may be employed.

INDEX TERM: FIBRINOLYSIS

HEMOSTASIS is a dynamic process generally appreciated in terms of either the coagulation system or platelet function, since much of our knowledge—until recently—has been restricted to the mechanism of thrombus formation. However, with increased understanding of the fibrinolytic system, cognizance of the role this system plays in normal hemostasis and disease states has become increasingly important. Its significance is emphasized by the attention currently given to thrombolytic therapy and the fact that abnormalities of either coagulation or fibrinolysis may mimic each other clinically.

Major developments in the field of fibrinolysis have influenced the therapy of thrombotic disease, and they will be increasingly translated into practical clinical laboratory testing. This review is intended to provide an update on these advances and some of the newer laboratory tests used to evaluate fibrinolysis.

In general biochemical terms, the fibrinolytic system is similar to the coagulation system but is functionally antithetic in that it digests fibrin and removes fibrin clot once hemostasis is achieved. Other functions attributed to it include tissue degradation as a basic response in a wide variety of neoplastic and non-neoplastic conditions.

Central to understanding the role of the fibrinolytic system in thrombosis is the concept that physiologic clot lysis occurs due to incorporation of fibrinolytic system components into the clot during its formation. These components include both activators and inhibitors of the system, which ideally produce a balanced, controlled lytic response. Under normal circumstances, fibrinolysis proceeds slowly relative to coagulation, thus allowing an effective hemostatic response to injury. Clinical events manifested by excessive bleeding or excessive clot formation may be due to inappropriately brisk or delayed fibrinolytic responses.

At the core of the fibrinolytic system is plasminogen,
TABLE 1
HUMAN PLASMA SERINE PROTEASE INHIBITORS

<table>
<thead>
<tr>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasminogen activator inhibitors</td>
</tr>
<tr>
<td>a,-plasmin inhibitor</td>
</tr>
<tr>
<td>a,-macroglobulin</td>
</tr>
<tr>
<td>Antithrombin III</td>
</tr>
<tr>
<td>Heparin co-factor II</td>
</tr>
<tr>
<td>C,-esterase inhibitor</td>
</tr>
<tr>
<td>Inter-alpha-inhibitor</td>
</tr>
<tr>
<td>Anti-chymotripsin</td>
</tr>
<tr>
<td>a,-antitrypsin</td>
</tr>
<tr>
<td>Protein C inhibitor</td>
</tr>
</tbody>
</table>

a zymogen that is converted via activators to the active enzyme plasmin. Hemostatic substrates of plasmin include fibrin, fibrinogen, the thrombin-activated forms of factors V and VIII:C, and platelet membrane glycoprotein Ib. Activation of plasminogen may be initiated by a variety of activators such as tissue plasminogen activator (t-PA), urokinase, or the contact system of coagulation.

The fibrinolytic response may be modulated in several ways. First, it may be inhibited by specific protein inhibitors such as plasminogen activator inhibitor (PAI), which inhibits tissue plasminogen activator, or a,-plasmin inhibitor (a,-PI), which inhibits plasmin. Second, it may be enhanced by cofactors such as fibrin, which dramatically promotes t-PA-induced activation of plasminogen. Third, it may be altered by changes in the production and release of plasminogen activator.

THE FIBRINOLYTIC SYSTEM

Plasminogen, plasmin, and plasmin inhibitors

Plasminogen is synthesized in the liver as a single-chain glycoprotein having a molecular weight of approximately 92 kd. Its plasma concentration is approximately 20 mg/dL, or 2 μM, and it may be recovered in the euglobulin fraction of plasma together with plasminogen activators. The plasminogen molecule contains 790 amino acid residues, 24 disulfide bridges, and five triple-loop structures called "kringles," so named after Scandinavian pastry having this form. These kringles contain lysine binding sites that mediate binding of plasminogen to substrates such as fibrin. When bound to fibrin, plasminogen may be more easily converted to plasmin and the effect of the plasmin is relatively localized to adjacent fibrin.

Native plasminogen has an NH2-terminal glutamic acid and is thus termed Glu-plasminogen. Plasmin may convert Glu-plasminogen by limited proteolysis to modified forms having an amino-terminal lysine, valine, or methionine. These forms are respectively termed Lys-plasminogen, Val-plasminogen, and Met-plasminogen. Either Glu-plasminogen or Lys-plasminogen may be converted to plasmin. This conversion is mediated by plasminogen activators, which will be discussed in the next section. The activation of plasminogen is achieved by cleavage of plasminogen at the arginine→valine bond to yield a two-chain, disulfide-linked molecule. Lys-plasminogen has a higher affinity for fibrin than does Glu-plasminogen and thus it is more rapidly converted to plasmin by certain activators such as tissue plasminogen activator. Therefore, the autocatalytic conversion of Glu-plasminogen into Lys-plasminogen by plasmin is an example of a positive feedback loop.

The two-chain, disulfide-linked, plasmin molecule is composed of a heavy chain and a light chain. The heavy chain possesses the five kringles with associated lysine binding sites that are responsible for binding plasminogen and plasmin to fibrin, tetrarctin, epsilon-amino caproic acid (EACA), a,-plasmin inhibitor (a,-PI), and histidine-rich glycoprotein (HRG). The light chain contains the active serine site responsible for proteolytic activity.

As a serine protease, plasmin is subject to inhibition by a variety of serine protease inhibitors. Human plasma contains at least nine different serine protease inhibitors (Table 1). In purified systems, plasmin is inhibited by a,-PI, a,-macroglobulin, a,-antitrypsin, antithrombin III, and C,-esterase inhibitor. However, plasmin generated in plasma is primarily and rapidly bound to a,-PI as 1:1 complex; a smaller proportion is bound more slowly to a,-macroglobulin. The binding of plasmin to a,-PI is essentially irreversible. The a,-PI is incorporated into fibrin clots where it is crosslinked to the clot by factor XIIIa. It is believed that this incorporation contributes to clot stabilization by preventing uncontroled lysis by plasmin. The concentration of a,-PI in plasma is approximately 1 μM. Since the plasma plasminogen level is twice that, or 2 μM, it follows that plasmin may be generated after a,-PI has been depleted. Plasmin formed when a,-PI is depleted may have significant effects on systemic fibrinogen levels, for example during thrombolytic therapy.

The availability of plasminogen for activation may be affected by certain plasma proteins and antifibrinolytic agents. Approximately 40% of plasminogen is bound to plasma HRG while smaller amounts are bound by tetrarctin and thrombospondin. Increased or decreased binding of plasminogen by these proteins may, respectively, either dampen or enhance the fibrinolytic response. EACA and tranexamic acid are therapeutic an-
T-PA pathway. This pathway has received the most attention recently. It consists of t-PA and a rapid-acting inhibitor of t-PA, termed plasminogen activator inhibitor (PAI). T-PA has been identified in several tissues and organs, including endothelium, from which it is secreted into the circulation. The release of t-PA from endothelium can be induced by a number of substances, which include thrombin, epinephrine, bradykinin, histamine, acetylcholine, platelet activating factor, and an analogue of vasopressin, DDAVP. Exercise and venous occlusion will also induce its release. It has been suggested that t-PA release may be under neurohumoral control via a t-PA releasing hormone from the pituitary.

T-PA has been extensively characterized and the genetic material that codes for its production, has been cloned. It is a serine protease synthesized as a single-chain glycoprotein with a molecular weight of approximately 60kd. Plasmin will convert it to a two-chain, disulfide-linked form. Both the single- and double-chain forms have enzymatic activity that is greatly enhanced in the presence of fibrin. This is because t-PA contains a finger domain and lysine binding sites in kringle structures that enable it to bind avidly to fibrin. The assembly of both t-PA and plasminogen onto a fibrin surface lowers the $K_m$ of plasminogen activation from 65 $\mu$M to 0.2 $\mu$M, thus making the reaction far more efficient. This feature contributes to the relative clot specificity of thrombolysis by t-PA.

The half-life of t-PA in the circulation is quite short (2–5 minutes) due to hepatic clearance and binding to fibrin. The plasma concentration of t-PA may be measured at different values depending on the method used. Antigen determinations yield values between 5 and 10 ng/mL, whereas activity measurements range from 0.1–0.4 IU/mL. This ratio of activity to antigen differs from highly purified standards of t-PA, which have a specific activity of 0.5–0.8 IU/ng. The reason for the low activity in plasma relative to the antigen level is that plasma contains an excess of a rapidly acting
plasminogen activator inhibitor (PAI; plasma concentration approximately 5–10 IU/mL). In all likelihood, most t-PA from blood taken under resting conditions circulates as a complex with PAI. Only when sufficient t-PA is released does it overcome the effects of PAI and become measurable. For this reason, it is currently believed that PAI may play a significant role in the regulation of fibrinolysis.

These are at least four immunologically distinct groups of PAI: the endothelial cell type (PAI-1), the placental type (PAI-2), protein C inhibitor, and protease nexin I. PAI-1 is found in endothelial cells, hepatocytes, granulosa cells, vascular smooth muscle cells, and platelet alpha-granules. PAI-1 constitutes about 60% of the total t-PA inhibitory capacity of plasma. It inhibits both t-PA and urokinase. PAI-2 is found in placenta and probably histiocytes/macrophages. It inhibits urokinase, to some extent the two-chain form of t-PA, and to a small degree the single-chain form of t-PA. Protease nexin I is a recently described broad-spectrum serine protease inhibitor that rapidly binds to thrombin when heparin is present. It also binds to single-chain t-PA and urokinase.

The exact role of the different types of PAI and the regulation of their levels remains to be clarified. PAI is incorporated into clots where it is believed to regulate the rate and extent of t-PA-induced lysis. Plasma t-PA inhibitory capacity appears to behave as an acute-phase reactant and it shows a distinct diurnal variation. The lowest values occur in mid-afternoon at a time when t-PA activity is at its peak. Stimulation of endothelial-cell PAI is produced by endotoxin and interleukin-1. Stanozolol, an anabolic steroid, lowers PAI activity in plasma when administered over a 2–3 week period. PAI may be neutralized by binding to activated protein C and this has been proposed as an explanation for the profibrinolytic properties of protein C.

Urokinase-dependent pathway. Recovered in small quantities from large volumes of urine or produced from human fetal kidney cell cultures, urokinase (UK) is a disulfide-linked two-chain serine protease distinct from t-PA. It directly converts plasminogen to plasmin. It is initially synthesized as an inactive single-chain protein, termed pro-urokinase (pro-UK) or single-chain urokinase-like plasminogen activator (scu-PA). Pro-UK may be identified as a normal component of plasma. The conversion of pro-UK to UK is mediated by plasmin, an effect that may be stimulated by heparin.

Pro-UK appears to be relatively clot-selective in its lytic properties whereas UK will cause both clot lysis and systemic fibrinogenolysis. The mechanism for this effect of pro-UK is currently being investigated, but may be related to the fact that free plasmin is generally not present in the circulation. Both PAI and C1-esterase inhibitor will inhibit UK; neither inhibits pro-UK.

Pharmacologic activators. The prototype activator used for therapeutic thrombolysis, SK, is a product of group C beta hemolytic streptococci. It activates plasminogen indirectly by binding to plasminogen. The SK-plasminogen activator complex in turn converts another molecule of plasminogen to plasmin. The SK-plasminogen activator complex may itself undergo plasmin-mediated conversion to SK-plasmin, which retains activator activity.

Either form of activator will exhibit activity against plasminogen regardless of the presence of fibrin. This means that plasmin will be formed both within a clot and in the circulation. The resulting changes in systemic levels of hemostatic components such as fibrinogen have been blamed for some of the bleeding complications of SK therapy, although this relationship is disputed. Patients with previous exposure to beta hemolytic streptococci will often have significant titers of antibody to SK, especially if the infection has been recent.

Because of the bleeding risk and occasional refractor-
FIGURE 4. Fibrin polymer, which is unstable, is stabilized by the action of factor XIIIa, which crosslinks adjacent molecules of fibrin.

FIGURE 5. Plasmin proteolysis of fibrinogen produces a variety of smaller-molecular-weight species, termed fragment X, fragment Y, fragment E, fragment D, and the beta chain peptide B-beta 1-42.
FIGURE 6. Plasmin proteolysis of stabilized fibrin yields a variety of products, some of which are distinct from those produced by degradation of fibrinogen. Two of these recently introduced as clinical laboratory tests include D-dimer and the beta chain peptide B-beta 15–42.

Laboratory tests

Four types of tests may be employed (Table 2): global tests of the pathway, measurement of specific components of the pathway, markers of lytic activity, and tests to predict re-thrombosis following lytic therapy.

Global tests of the fibrinolytic pathway. These tests are all meant to indicate the overall rate or extent of fibrinolytic activity in a patient sample. They vary in complexity and sensitivity. The simplest test, whole-blood clot lysis, may be performed by drawing blood into a tube without anticoagulant, allowing it to clot, and observing the clot. Under normal circumstances the clot will remain intact for at least 24 hours, reflecting a global balance in favor of inhibition of lysis. Blood from patients with bleeding due to excessive free plasmin or plasminogen activator will exhibit clot lysis within hours. The test is charmingly simple but is probably too insensitive to be of much value except in cases of brisk fibrinolytic bleeding.

Whole-blood clot lysis may also be evaluated using a thromboelastograph, which is an instrument that imparts a mechanical force to blood placed in a stainless steel cup. A pin placed into the blood senses both clot development and dissolution. The device can be used near the patient's bedside; lytic activity, if present, is evident within minutes to a few hours. It has recently been found useful in cases of liver transplant and surgery of large vessels.

Other uses may be made of whole blood. Clot lysis may be evaluated using clots from platelet-rich or platelet-poor plasma, though in general this approach is not much better for clinical purposes than the whole-blood technique. This is, of course, in marked contrast to the situation with the coagulation cascade wherein the PT and APTT represent significant advances over the whole-blood clotting time.

The euglobulin fraction of plasma contains fibrinogen, plasminogen activator, and plasminogen, but not
inhibitors of fibrinolysis. A clot formed from the euglobulin fraction will lyse readily (less than one hour) if there is excessive plasmin or plasminogen activator. Whereas a deficiency of α2-PI will cause rapid whole-blood clot lysis, it will not affect the euglobulin clot lysis time as readily since there is little α2-PI in the usual euglobulin preparation. Lytic activity may also be assessed by application of small aliquots of the euglobulin fraction, lysis times or lysis zones using this fraction. Zones of clearing indicate lysis and zone size correlates with the amount of lytic activity present. Since inhibitors are removed by preparation of the euglobulin fraction, lysis times or lysis zones using this fraction should be more sensitive tests for pro-fibrinolytic proteins than those using whole blood or plasma.

Measurement of specific components of the fibrinolytic pathway. The introduction of chromogenic and fluorogenic substrates has made possible the measurement of functional levels of plasminogen, α2-PI, t-PA, urokinase, and PAI. α2-PI uses the same substrate, but the test measuring α2-PI is added to the reaction mixture. The principle behind this approach is that plasmin substrate and plasminogen are kept in excess, and color or fluorescence develops in proportion to the amount of enzyme added to the reaction mixture. Variable substrates are available and instrumentation may be as humble as a simple spectrophotometer or as sophisticated as an automated centrifugal analyzer. In general, the assays are not difficult since many are available commercially in kit form.

Plasminogen is usually measured by adding excess SK to a plasma sample. This converts all the plasminogen to SK-plasminogen complexes, which have amidolytic activity against the substrate. In the simplified form shown below, the substrate is H-D-val-leu-lys-paranitroaniline (pNA) and the reaction product is monitored at 405 nm:

\[
\text{Plasminogen} + \text{SK} \rightarrow \text{Plasminogen} \cdot \text{SK} \\
\text{Plasminogen} \cdot \text{SK} + \text{H-D-val-leu-lys-pNA} \rightarrow \text{Plasminogen} \cdot \text{SK} + \text{H-D-val-leu-lys} + \text{pNA (A}_{405}\text{)}
\]

The assumption, of course, is that plasminogen will function as well when physiologic activators such as t-PA are employed as it does when SK is used. The normal level for plasminogen is about 2 μM (approximately 20 mg/dL, 2.4–3.8 CTAU/mL).

The test measuring α2-PI uses the same substrate, but it is performed by adding plasmin to the plasma sample. Available α2-PI in the sample will neutralize plasmin on a 1:1 stoichiometric basis. If an appropriate amount of plasmin has been added, there will be a slight excess available for amidolysis of the substrate. The result is compared with the amount of color product formed when no α2-PI is added to the reaction mixture. The amount by which the sample has diminished the color product compared with the blank is proportional to the amount of plasmin inhibitor present. In this case α2-PI is the inhibitor being measured since the time of incubation of sample and plasmin together is so short that only a rapid-acting inhibitor will be effective. The normal level for α2-PI is about 1 μM (approximately 80%–120% of that in pooled normal plasma).

An assay scheme similar to that for plasminogen exists for measuring t-PA and PAI and is based on recently developed t-PA-specific substrates, but most methods described have used the plasmin substrates in an indirect assay. The principle behind this approach is that plasmin substrate and plasminogen are kept in excess, solubilized fibrin is added as a cofactor, and the plasma sample is added. Color develops over the course of several hours as t-PA activates plasminogen and substrate is hydrolyzed by the formed plasmin. PAI is measured by adding exogenous t-PA to the reaction mixture and measuring neutralization of color development by PAI in the plasma sample.

There remain several difficulties with the measurement of t-PA. In baseline samples, t-PA levels are exceedingly low, approximately 0.1–0.4 IU/mL, whereas there is approximately 5–10 IU/mL of PAI. It would seem, given the excess of PAI, that t-PA should not be
midway between systolic and diastolic pressure, leave it
blood sample, inflate a blood pressure cuff to a point
approach with arm occlusion has been to draw a baseline
perform a DDAVP infusion or tourniquet arm occlusion
vasopressin analogue DDAVP. Since abnormalities in
venous occlusion, exercise, or the administration of the
modification.

and commercially available material is still undergoing
preparations from individual laboratories have been used
and commercially available material is still undergoing
modification.

In contrast to resting levels of t-PA, plasma levels rise
appreciably when endothelial cells are stimulated by
venous occlusion, exercise, or the administration of the
vasopressin analogue DDAVP. Since abnormalities in
this response have been described, stimulated t-PA
levels are of interest, but the laboratory must be able to
perform a DDAVP infusion or tourniquet arm occlusion
technique in some standardized manner. The usual ap-
proach with arm occlusion has been to draw a baseline
blood sample, inflate a blood pressure cuff to a point
midway between systolic and diastolic pressure, leave it
inflated for 15 minutes, and draw a blood sample.32 The
DDAVP infusion technique has generally been to give
0.4 μg/kg intravenously for a 10-minute period and to
draw pre-infusion and post-infusion samples.63 Levels of
t-PA antigen after stimulation are approximately 10–20
ng/mL whereas those of t-PA activity are approximately
0.6–5.4 IU/mL. The laboratory must use caution to es-
establish its own normal range with this technique.

Markers of lytic activity. There are direct and indirect
markers of fibrinolytic activity. Plasminogen and α2-PI
can be used indirectly to infer that lytic activity exists.
During intense lytic therapy the levels of these proteins
decrease predictably.34,38 As plasmin is generated, the
level of α2-PI drops until it approaches 0%–10% of the
pretreatment level (normally about 1 μM). At this
point, plasminogen will be approximately 50%–60% of
its pretreatment level (normally about 2 μM). Further
administration of the lytic agent will deplete plasmino-
gen even more. Although a similar pattern of change
has been described in patients treated for acute pro-
myelocytic leukemia (FAB M-3),39 a careful search for
this pattern has not been made in more frequently en-
countered clinical situations such as postoperative
bleeding.

Depletion of plasma fibrinogen has been more
frequently used as an indirect marker of lytic activity
and in fact the term "lytic state" has been applied when
the level falls below 100 mg/dL. Even though serious
bleeding may occur without a lytic state, measurement
of fibrinogen is important because low levels have been
blamed for many bleeding episodes.

There are three types of fibrinogen measurement
(Table 3), based on thrombin clotting, precipitation, or
immunologic procedures.40 The method used most often
in clinical laboratories is an adaptation of the Clauss
method, and the materials are available in kit form. It is
an example of a thrombin clotting technique that is
based on the rate of fibrin formation and not on the
amount of total protein in the final clot. Assessment of
total protein in the clot may be achieved by chemical
assay, weight measurement, or ultraviolet absorption.
Precipitation techniques are based on either heat or salt
(sodium sulfite, ammonium sulfate) and take advantage
of the fact that fibrinogen is one of the least soluble
plasma proteins. Immunologic methods include a
variety of procedures—latex agglutination, immunodif-
fusion, immunoelectrophoresis, radioimmunoassay, and
nephelometry.

The main difficulty with fibrinogen determinations
during lytic therapy is that fibrinogen split products
(FSPs) may interfere with the measurement, and the de-
gree of interference depends on the method used. The
Clauss technique is generally claimed to be sensitive to
FSPs and to give falsely low fibrinogen values.35,36 This
may be a greater problem when a fibrometer (BBL, Bal-
timore, MD) is used than when the DuPont ACA
(Wilmington, DE) is used.41 Precipitation techniques,
on the other hand, are claimed to be less affected by
FSPs and therefore may give more accurate values. The
extent to which these claims are true probably varies de-
pending on the types of FSPs present, the type of lytic
agent used, and the accuracy with which FSPs are quan-
titated.

Until recently, tests for FSPs have been significantly
limited because the antibodies used to perform the test
could not distinguish between degradation products of
fibrin and those of fibrinogen. Split products of fibrin
would be evidence of secondary (physiologic) fibrino-
lysis, which accompanies disseminated intravascular coag-
ulation, the postoperative state, or deep vein/peripheral
arterial thromboembolism. Split products of fibrinogen,
however, would be evidence of primary fibrinogenolysis,
a condition in which pathologic proteolytic activity exists and is directed at circulating fibrinogen.

Antibodies are now available that specifically recognize fibrin degradation products. One that has been extensively investigated and is now available to clinical laboratories recognizes the D domains of fibrin after they have been crosslinked by factor XIII and digested by plasmin.

The test for D-dimer can be performed either as a latex agglutination procedure or as a more sensitive ELISA technique. Since the antibody does not react with fibrinogen, plasma samples may be used for the test, obviating the need for specially preserved serum samples that are currently needed for fibrin(ogen) split product determinations. D-dimer levels are well below 1 μg/mL in normal individuals and may range up to 32 μg/mL during intense lytic therapy or in patients with secondary fibrinolysis. This is in distinct contrast to values obtained by serum fibrin(ogen) split product assays, which may range up to 1–2 mg/mL. Such readings may well be artifically high due to residual poorly clottable fibrinogen in the serum. They may also be due to different sensitivities of serum assays produced by different manufacturers. Of the two most popular ones available, one is more sensitive to fragments D and E and less sensitive to fragment X and fibrinogen than the other.

Other antibodies to fibrin degradation products are available, but have been used less in the clinical laboratory. Plasmin degradation of fibrin yields the beta-chain peptide B-beta 15–42 whereas degradation of fibrinogen yields B-beta 1–42. Since these fragments are measured by ELISA, the technique is extremely sensitive (lower limit about 4.5 pmol/mL). It unfortunately requires preparation of a fibrinogen-free sample using bentonite precipitation, ethanol precipitation, filtration, or heat denaturation.

Elevated levels of both the 1–42 and 15–42 fragments during lytic therapy suggest that both fibrin clot and circulating fibrinogen are being degraded. Elevated levels of B-beta 15–42 following cessation of t-PA administration and long after t-PA has cleared from the circulation suggest sustained clot lysis due to t-PA incorporated in the clot. This effect is less apparent when SK is used. Indeed, a greater magnitude and duration of elevation of D-dimer and B-beta 15–42 have been observed with t-PA compared with SK, suggesting more intense and persistent fibrinolysis with t-PA.

Tests to predict re-thrombosis following lytic therapy. Following lytic therapy there is a significant risk of re-thrombosis. Tests to predict thrombosis (hypercoagulability) or the potential for re-occlusion have been numerous and have been largely unsuccessful except in cases of familial abnormalities. However, two, for fibrinopeptide A and soluble fibrin, hold promise. Fibrinopeptide A may be measured by radioimmunoassay or ELISA and is normally less than 2 ng/mL in plasma. Elevated levels have been observed in a wide variety of situations such as disseminated intravascular coagulation, cardiac surgery, unstable angina, myocardial infarction, peripheral arterial or venous thromboembolism, and following lytic therapy. In fact, the levels rise during infusion of t-PA, suggesting that either thrombin in the clot is liberated into the circulation or the antibody used in the test is cross-reacting with some other species of fibrin(ogen). Rapid re-thrombosis of coronary arteries has been associated with elevated FpA levels following t-PA, despite the administration of heparin.

The attempt to measure circulating soluble fibrin has been long and difficult. The protamine sulfate test and others like it (ethanol gelation) have not been particularly successful. An electrophoretic technique recently developed at The Cleveland Clinic for trials of rt-PA (Table 4), the main test required, from a practical standpoint, is for fibrinogen. Clinical decisions to stop lytic therapy or to administer transfusion are based only partially on the fibrinogen level and even then only when the level drops below 50 mg/dL (Clauss method-fibrometer).

If extensive testing is performed, there are significant problems with sample handling. Sample preservation is critical because in vitro effects of the lytic agent may occur. Protease inhibitors such as aprotinin (Trasylo) and PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) have been used with some success. Monoclonal antibodies to t-PA have also been
used successfully. It has generally been preferable to test samples before freezing them, though of course this isn’t always convenient. An accurate assessment of FpA levels requires extraordinary attention to venipuncture technique, knowledge of previous intravenous lines or venipunctures, and use of protease inhibitors in the sample tubes. Spurious elevations in plasma FpA due to artifactual sample handling or the presence of indwelling catheters have been a significant problem.

Diagnostic testing. Abnormalities of the fibrinolytic system that cause bleeding (Table 5) are deficiency of α2-plasmin inhibitor, deficiency of plasminogen activator inhibitor, or excess plasminogen activator.6,6 Although not typically considered as part of the fibrinolytic system, factor XIII deficiency will cause bleeding since the clot that forms is unstable and is more susceptible to plasmin degradation.26 The usual screening test for factor XIII, clot stability in monochloroacetic acid, is not especially sensitive to factor XIII deficiency, nor is it specific since it will be abnormal in α2-PI deficiency.

Abnormalities of the fibrinolytic system that cause thrombosis (Table 6) include plasminogen deficiency (either low antigen level or defective molecule), t-PA deficiency, and excess PAI.4,6 A deficiency of t-PA following an appropriate stimulus such as DDAVP may be due to a defect in production/release, in which case the antigen level will be low, or it may be due to a functional deficiency. Functional deficiencies of t-PA may be due to excess PAI. High levels of PAI have now been described in association with deep vein thrombosis, myocardial infarction, hyperlipoproteinemia, and non-specific acute illnesses.4,6,19,50-52 The relationship of PAI to the mechanism of these various disorders is still being investigated.

SUMMARY

The complexity of the fibrinolytic system is now known to rival that of the coagulation cascade and platelet function at a biochemical level. Its clinical importance in cardiovascular disease is underscored by recent attempts to dissolve thrombi and ongoing efforts to define abnormalities responsible for either hemorrhage or thrombosis. Laboratory tests to study fibrinolysis have advanced significantly in the past ten years and now allow better characterization of biologic samples. Ingenuity in applying these measurements to disease states will determine how useful they are to patient care.

REFERENCES


TABLE 4
LABORATORY TESTS PERFORMED AT CLEVELAND CLINIC IN PATIENTS RECEIVING t-PA

<table>
<thead>
<tr>
<th>Test</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT</td>
<td></td>
</tr>
<tr>
<td>APTT</td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td></td>
</tr>
<tr>
<td>Plasminogen</td>
<td></td>
</tr>
<tr>
<td>α2-Plasmin inhibitor</td>
<td></td>
</tr>
<tr>
<td>Fibrinogen split products</td>
<td></td>
</tr>
<tr>
<td>D-dimer</td>
<td></td>
</tr>
<tr>
<td>B-bet 1-42</td>
<td></td>
</tr>
<tr>
<td>B-bet 15-42</td>
<td></td>
</tr>
<tr>
<td>Soluble fibrin</td>
<td></td>
</tr>
<tr>
<td>Fibrinopeptide A</td>
<td></td>
</tr>
</tbody>
</table>

PT = prothrombin time; APTT = activated partial thromboplastin time.

12. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J


